Acute myeloid leukemia (AML)

AML is the most common form of leukemia and progresses quickly if left untreated, leading to death within a few months after diagnosis. Various modalities of chemotherapy followed by allo-HCT in the cases associated with the most severe prognosis have improved disease free survival in AML patients.

A high unmet need remains to improve treatment outcomes through the prevention of relapses and transplant-related toxicities such as graft-versus-host disease (GvHD).

Despite progress in reducing transplant-related mortality, no major clinical improvements in post-transplant relapse incidences and overall survival have been achieved over the last four decades. Approximately 40% of post-HCT AML patients will relapse and face a dismal prognosis with a 2-year survival of less than 20%.

Mocravimod, a modulator of sphingosine-1-phosphate (S1P) receptors, has the potential to enhance the curative potential of allogeneic HCT in hematological malignancies in general and in AML specifically.